Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics: 8 sponsored US clinical trials, 1 recruiting.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, Overweight, or Chronic Weight Management, with 2 trials.
Upper-quartile sponsor footprint
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588
Aleniglipron Phase 2 Body Composition Study
NCT07169942
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06703021
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
NCT05893043
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
NCT05762471
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics pipeline
1 recruiting of 8 indexed (13% open); 2 completed (25%).
Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Obesity, Overweight, or Chronic Weight Management (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics page
8 registered trials is a research-attention snapshot, not an endorsement of Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics or any single study.
- 1 of Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity, Overweight, or Chronic Weight Management is the condition Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity, Overweight, or Chronic Weight Management trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.